Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu

In today's Pharmaceutical Executive Daily, Rigel Pharmaceuticals enters an exclusive global licensing agreement with Arvinas and Pfizer for Veppanu, Eli Lilly releases data from two late-phase trials showing patients maintained meaningful weight loss after transitioning from higher-dose injectable GLP-1 therapies, and Hope Mueller argues that true pharmaceutical expertise is defined not just by having answers but by recognizing when you need a reset.